Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: Results from the population-based PROFILES registry

Gynecologic Oncology

Volumn 135, Issue 3, 2014, Pages 510-517

  Ezendam, Nicole P M ^a,b   Pijlman, Brenda ^c   Bhugwandass, Celine ^c   Pruijt, Johannes F M ^c   Mols, Floortje ^a,b   Vos, M Caroline ^d   Pijnenborg, Johanna M A ^d   Van De Poll Franse, Lonneke V ^a,b  

^a TILBURG UNIVERSITY   (Netherlands)

^b Eindhoven Cancer Registry   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

Author keywords

Cancer; Chemotherapy; Chemotherapy induced peripheral neuropathy; Health related quality of life; Neuropathy; Neurotoxicity; Oncology; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; ETOPOSIDE; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ARTICLE; BODY IMAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVOR; CHEMOTHERAPY INDUCED EMESIS; COMORBIDITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FINANCIAL DEFICIT; HAIR LOSS; HAND PARESTHESIA; HUMAN; INSOMNIA; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OSTEOARTHRITIS; OVARY CANCER; PAIN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RISK FACTOR; SEXUALITY; SKIN TINGLING; SOCIAL INTERACTION; SOCIAL STATUS; TUMOR DIFFERENTIATION; CHEMICALLY INDUCED; COHORT ANALYSIS; OVARIAN NEOPLASMS; PATHOLOGY; SURVIVAL;

AGED; COHORT STUDIES; FEMALE; HUMANS; OVARIAN NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL ANALYSIS;

EID: 84920747132     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.09.016     Document Type: Article

References (37)

1. Sukel MP, van de Poll-Franse LV, Nieuwenhuijzen GA, Vreugdenhil G, Herings RM, Coebergh JW, et al. Substantial increase in the use of adjuvant systemic treatment for early stage breast cancer reflects changes in guidelines in the period 1990-2006 in the southeastern Netherlands. Eur J Cancer 2008;44:1846-54.
2. Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, et al. Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer 2010;46:1101-10.
3. Elferink MA, van Steenbergen LN, Krijnen P, Lemmens VE, Rutten HJ, Marijnen CA, et al. Marked improvements in survival of patients with rectal cancer in the Netherlands following changes in therapy, 1989-2006. Eur J Cancer 2010;46: 1421-9.
4. Zanders MM, Boll D, van Steenbergen LN, van de Poll-Franse LV, Haak HR. Effect of diabetes on endometrial cancer recurrence and survival. Maturitas 2013;74: 37-43.
5. Beijers AJ, Jongen JL, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 2012;70:18-25.
6. Pachman DR, Barton DL, Watson JC, Loprinzi CL. Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 2011;90:377-87.
7. Mols F, Beijers T, Vreugdenhil G, de Poll-Franse LV Van. Chemotherapy-induced peripheral neuropathy and its associationwith quality of life: a systematic review. Support Care Cancer 2014;22:2261-9.
8. Gutierrez-Gutierrez G, Sereno M, Miralles A, Casado-Saenz E, Gutierrez-Rivas E. Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies. Clin Transl Oncol 2010;12:81-91.
9. Cella D, Peterman A, Hudgens S, Webster K, Socinski MA. Measuring the side effects of taxane therapy in oncology: the functional assessment of cancer therapy-taxane (FACT-taxane). Cancer 2003;98:822-31.
10. Driessen CM, de Kleine-Bolt KM, Vingerhoets AJ, Mols F, Vreugdenhil G. Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 2012;20:877-81.
11. Kim BJ, Park HR, Roh HJ, Jeong DS, Kim BS, Park KW, et al. Chemotherapy-related polyneuropathy may deteriorate quality of life in patients with B-cell lymphoma. Qual Life Res 2010;19:1097-103.
12. Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 2013;31:2699-707.
13. Morita S, Kobayashi K, Eguchi K, Matsumoto T, Shibuya M, Yamaji Y, et al. Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. Jpn J Clin Oncol 2003;33:470-6.
14. Ramchandren S, Leonard M, Mody RJ, Donohue JE, Moyer J, Hutchinson R, et al. Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 2009;14:184-9.
15. Sorbe B, Graflund M, Nygren L, Horvath G, Swahn M, Boman K, et al. A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol 2012;40:773-81.
16. Calhoun EA, Welshman EE, Chang CH, Lurain JR, Fishman DA, Hunt TL, et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 2003;13:741-8.
17. van de Poll-Franse LV, Horevoorts N, van Eenbergen M, Denollet J, Roukema JA, Aaronson NK, et al. The Patient Reported Outcomes Following Initial treatment and Long term Evaluation of Survivorship registry: scope, rationale and design of an infrastructure for the study of physical and psychosocial outcomes in cancer survivorship cohorts. Eur J Cancer 2011;47:2188-94.
18. Van Duijn C, Keij I. Sociaal-economische status indicator op postcodeniveau [in Dutch]. Maandstatistiek van de bevolking, 50; 2002 32-5.
19. Sangha O, Stucki G, Liang MH, Fossel AH, Katz JN. The Self-Administered Comorbidity Questionnaire: a new method to assess comorbidity for clinical and health services research. Arthritis Rheum 2003;49:156-63.
20. Niezgoda HE, Pater JL. A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res 1993;2:319-25.
21. Fayers P, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, et al. The EORTC QLQ-C30 scoring manual. 3rd ed. Brussel: EORTC; 2001.
22. Greimel E, Bottomley A, Cull A,Waldenstrom AC, Arraras J, Chauvenet L, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003;39:1402-8.
23. Cocks K, King MT, Velikova G, Martyn St-James M, Fayers PM, Brown JM. Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. J Clin Oncol 2011;29:89-96.
24. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care 2003;41:582-92.
25. Stavraka C, Ford A, Ghaem-Maghami S, Crook T, Agarwal R, Gabra H, et al. A study of symptoms described by ovarian cancer survivors. Gynecol Oncol 2012;125:59-64.
26. Richter R, Oskay-Oezcelik G, Chekerov R, Pilger A, Hindenburg HJ, Sommer H, et al. Health-related quality of life during sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: a multicenter phase ii study of the North Eastern German Society of Gynecological Oncology. Anticancer Res 2012;32:3969-76.
27. Koike H, Tanaka F, Sobue G. Paraneoplastic neuropathy: wide-ranging clinicopathological manifestations. Curr Opin Neurol 2011;24:504-10.
28. Gregg EW, Sorlie P, Paulose-Ram R, Gu Q, Eberhardt MS, Wolz M, et al. Prevalence of lower-extremity disease in the US adult population >=40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004;27:1591-7.
29. Cull A, Howat S, Greimel E, Waldenstrom AC, Arraras J, Kudelka A, et al. Development of a European Organization for Research and Treatment of Cancer questionnaire module to assess the quality of life of ovarian cancer patients in clinical trials: a progress report. Eur J Cancer 2001;37:47-53.
30. Balayssac D, Ferrier J, Descoeur J, Ling B, Pezet D, Eschalier A, et al. Chemotherapy-induced peripheral neuropathies: from clinical relevance to preclinical evidence. Expert Opin Drug Saf 2011;10:407-17.
31. Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 2013;309:1359-67.
32. Kavanagh JJ. Docetaxel in the treatment of ovarian cancer. Oncology (Williston Park) 2002;16:73-81.
33. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004;96:1682-91.
34. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2014;15:e250-1.
35. Katsumata N, Yasuda M, Isonishi S, Takahashi F, Michimae H, Kimura E, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol 2013;14:1020-6.
36. Harano K, Terauchi F, Katsumata N, Takahashi F, Yasuda M, Takakura S, et al. Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a firstline treatment for stage II-IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016). Ann Oncol 2014;25:251-7.
37. Chan JK, Tian C, Fleming GF,Monk BJ, Herzog TJ, Kapp DS, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets ofwomenwith early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study. Gynecol Oncol 2010;116:301-6.